Site search
2960 results for '' found
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer [CAR NK] Cell Therapy, in Subjects with Immune-Mediated Diseases (NCT06733935)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer [CAR NK] Cell Therapy, in Subjects with Immune-Mediated Diseases (NCT06733935)
/
Perioperative Medicine Platform Trial (NCT07186634)
Perioperative Medicine Platform Trial (NCT07186634)
/
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (NCT07104565)
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (NCT07104565)
/
LOTUS - Low dose combinations to improve stroke outcomes (ACTRN12624001279516)
LOTUS - Low dose combinations to improve stroke outcomes (ACTRN12624001279516)
/
Screening for cardiac amyloidosis in patients with new conduction disease at the Alfred (ACTRN12624000520538)
Screening for cardiac amyloidosis in patients with new conduction disease at the Alfred (ACTRN12624000520538)
/
Moderately accelerated pacing in patients with cardiac amyloidosis (ACTRN12625000386437)
Moderately accelerated pacing in patients with cardiac amyloidosis (ACTRN12625000386437)
/
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients with Newly Diagnosed FLT3-ITD + Acute M
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients with Newly Diagnosed FLT3-ITD + Acute M
/
Alfred Mental & Addiction Health Cultural Safety, Equity and Access Strategic Direction 2026-2028 pdf
AMAH_CSEA_Strategy_Direction_2026-2028_Digital.pdf
https://app.prompt.org.au/download/267594?code=603bc6eb-41c1-4938-89eb-81c128541527
Transition_Care_Program_Client_Service_Agreement.pdf